Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double‐knockout mice
Open Access
- 4 March 2013
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 27 (6), 2484-2495
- https://doi.org/10.1096/fj.12-224170
Abstract
Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder caused by the lack of functional dystrophin. There is no cure, but several clinical trials aimed to restore the synthesis of functional dystrophin are underway. The dystrophin levels needed for improvement of muscle pathology, function, and overall vitality are not known. Here, we describe the mdx/utrn–/–/XistΔhs mouse model, which expresses a range of low dystrophin levels, depending on the degree of skewing of X inactivation in a utrophin-negative background. Mdx/utrn–/– mice develop severe muscle weakness, kyphosis, respiratory and heart failure, and premature death closely resembling DMD pathology. We show that at dystrophin levels < 4%, survival and motor function in these animals are greatly improved. In mice expressing >4% dystrophin, histopathology is ameliorated, as well. These findings suggest that the dystrophin levels needed to benefit vitality and functioning of patients with DMD might be lower than those needed for full protection against muscle damage.—Van Putten, M., Hulsker, M., Young, C., Nadarajah, V. D., Heemskerk, H., van der Weerd, L., 't Hoen, P. A. C., van Ommen, G. J. B., Aartsma-Rus, A. M. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J. 27, 2484–2495 (2013). www.fasebj.orgKeywords
This publication has 36 references indexed in Scilit:
- Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skippingHuman Molecular Genetics, 2012
- The Effects of Low Levels of Dystrophin on Mouse Muscle Function and PathologyPLOS ONE, 2012
- Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV VectorMolecular Therapy, 2012
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Systemic Administration of PRO051 in Duchenne's Muscular DystrophyThe New England Journal of Medicine, 2011
- Marginal Level Dystrophin Expression Improves Clinical Outcome in a Strain of Dystrophin/Utrophin Double Knockout MicePLOS ONE, 2010
- Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophyAnnals of Neurology, 2010
- Prevention of Dystrophic Pathology in Severely Affected Dystrophin/Utrophin-deficient Mice by Morpholino-oligomer-mediated Exon-skippingMolecular Therapy, 2010
- Serum levels of vascular endothelial growth factor elevated in patients with muscular dystrophyBrain & Development, 2009
- Generation and Characterization of Transgenic Mice with the Full-length Human DMD GenePublished by Elsevier BV ,2008